LXRX News and Press, Lexicon Pharmaceuticals Inc. From 03/17/22

Lexicon Pharmaceuticals (NASDAQ:LXRX) has entered into a $150M loan facility with Oxford Finance to provide commercial preparations and support the potential launch of sotagliflozin in heart failure. The loan facility consists of four tranches. The first three are for $25M each, while the fou...

THE WOODLANDS, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it entered into a loan facility with Oxford Finance LLC that provides up to $150 million in borrowing capacity designed primarily to support commercial preparations ...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Lexicon shares were hit hard on the company's announcement that it will withdraw and resubmit its sotagliflozin NDA due to a technical omission. The heart failure space is getting more interesting as positive clinical data on SGLT-2 drugs are driving recommendations that they become a...

This isn't the best way for a company to begin its work week. On Monday, shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) fell sharply earthward, losing over 27% of their value. This followed the release of the biotech's fourth-quarter results, accompanied by a discouraging update a...

Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2021 Earnings Conference Call February 28, 2022 8:00 A.M. ET Company Participants Chas Schultz - Executive Director, Corporate Communications and Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President and Chief Financial Officer...

Gainers: IntriCon (NASDAQ:IIN) +37%. NeuroSense Therapeutics (NASDAQ:NRSN) +28%. Homology Medicines (NASDAQ:FIXX) +17%. CorMedix (NASDAQ:CRMD) +14%. Reata Pharmaceuticals (NASDAQ:RETA) +13%. Losers: Aurinia Pharmaceuticals (NASDAQ:AUPH) -29%. Lexicon Pharmac...

The development stage biopharma company Lexicon Pharmaceuticals (NASDAQ:LXRX) has lost ~18% in the pre-market Monday after announcing that it decided to voluntarily withdraw the U.S. marketing application of sotagliflozin to correct a technical issue. In December, Lexicon (LXRX) announce...

Lexicon Pharmaceuticals press release (NASDAQ:LXRX): Q4 GAAP EPS of -$0.17 beats by $0.01. Revenue of $0.01M (-95.0% Y/Y). For further details see: Lexicon Pharmaceuticals GAAP EPS of -$0.17 beats by $0.01, revenue of $0.01M